Green Tea May Protect Brain Cells Against Parkinson’s Disease
New study published in Biological Psychiatry
Philadelphia, PA, December 13, 2007 – Does the consumption of green tea, widely touted to have beneficial effects on health, also protect brain cells? Authors of a new study being published in the December 15th issue of Biological Psychiatry share new data that indicates this may be the case. The authors investigated the effects of green tea polyphenols, a group of naturally occurring chemical substances found in plants that have antioxidant properties, in an animal model of Parkinson’s disease.
Parkinson’s disease is a progressive, degenerative disorder of the central nervous system, resulting from the loss of dopamine-producing brain cells, and there is presently no cure. According to Dr. Baolu Zhao, corresponding and senior author on this article, current treatments for Parkinson’s are associated with serious and important side effects. Their previous research has indicated that green tea possesses neuroprotective effects, leading Guo and colleagues to examine its effects specifically in Parkinson’s. The authors discovered that green tea polyphenols protect dopamine neurons that increases with the amount consumed. They also show that this protective effect is mediated by inhibition of the ROS-NO pathway, a pathway that may contribute to cell death in Parkinson’s.
Considering the popularity of green tea beverages worldwide, there is enormous public interest in the health effects of its consumption. John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, reminds us that “many health-related claims have been made for a wide variety of naturally-occurring substances and many of these claims, as in the case of St. John’s Wort and Ginko Biloba, have not held up in rigorous clinical studies. Thus, it is extremely important to identify the putative neuroprotective mechanisms in animal models, as Guo and colleagues have begun to do for Parkinson’s disease.”
Dr. Zhao’s hope is that eventually “green tea polyphenols may be developed into a safe and easily administrable drug for Parkinson’s disease.” Dr. Krystal agrees, that “if green tea consumption can be shown to have meaningful neuroprotective actions in patients, this would be an extremely important advance.”
# # #
Notes to Editors:
The article is “Protective Effects of Green Tea Polyphenols in the 6-OHDA Rat Model of Parkinson's Disease Through Inhibition of ROS-NO Pathway” by Shuhong Guo, Jingqi Yan, Tangbin Yang, Xianqiang Yang, Erwan Bezard and Baolu Zhao. Drs. Guo, Yan, and Zhao are affiliated with State Key Laboratory of Brain & Cognitive Science, Institute of Biophysics, Academia Sinica in Beijing, China. Dr. Yan is also with the Graduate School of Chinese Academy of Sciences in Beijing, China. Dr. Zhao is also with the E-Institutes of Shanghai Municipal Education Commission, China. Dr. T. Yang is from the Space Cell and Molecular Biology Laboratory, Institute of Space and Medico-Engineering, Beijing, China. Dr. X. Yang is affiliated with the Department of Tea Science, Zhejiang University in Hangzhou, China. Dr. Bezard is with the National Center for Scientific Research (The Centre National de la Recherche Scientifique) in Bordeaux, France. The article appears in Biological Psychiatry, Volume 62, Issue 12 (December 15, 2007), published by Elsevier.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at (215) 239-3674 or email@example.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).